Current Opinion in Ophthalmology最新文献_第9页

Future directions of glaucoma treatment: emerging gene, neuroprotection, nanomedicine, stem cell, and vascular therapies. 青光眼治疗的未来方向：新兴基因、神经保护、纳米医学、干细胞和血管治疗。

IF 3.7 2区医学

Current Opinion in Ophthalmology Pub Date : 2024-03-01 Epub Date: 2023-11-01 DOI: 10.1097/ICU.0000000000001016

Elizabeth C Ciociola, Elise Fernandez, Mary Kaufmann, Meredith R Klifto

{"title":"Future directions of glaucoma treatment: emerging gene, neuroprotection, nanomedicine, stem cell, and vascular therapies.","authors":"Elizabeth C Ciociola, Elise Fernandez, Mary Kaufmann, Meredith R Klifto","doi":"10.1097/ICU.0000000000001016","DOIUrl":"10.1097/ICU.0000000000001016","url":null,"abstract":"Purpose of review: The aim of this article is to summarize current research on novel gene, stem cell, neuroprotective, nanomedicine, and vascular therapies for glaucoma.Recent findings: Gene therapy using viral vectors and siRNA have been shown to reduce intraocular pressure by altering outflow and production of aqueous humor, to reduce postsurgical fibrosis with few adverse effects, and to increase retinal ganglion cell (RGC) survival in animal studies. Stem cells may treat glaucoma by replacing or stimulating proliferation of trabecular meshwork cells, thus restoring outflow facility. Stem cells can also serve a neuroprotective effect by differentiating into RGCs or preventing RGC loss via secretion of growth factors. Other developing neuroprotective glaucoma treatments which can prevent RGC death include nicotinamide, the NT-501 implant which secretes ciliary neurotrophic factor, and a Fas-L inhibitor which are now being tested in clinical trials. Recent studies on vascular therapy for glaucoma have focused on the ability of Rho Kinase inhibitors and dronabinol to increase ocular blood flow.Summary: Many novel stem cell, gene, neuroprotective, nanomedicine, and vascular therapies have shown promise in preclinical studies, but further clinical trials are needed to demonstrate safety and efficacy in human glaucomatous eyes. Although likely many years off, future glaucoma therapy may take a multifaceted approach.","PeriodicalId":50604,"journal":{"name":"Current Opinion in Ophthalmology","volume":" ","pages":"89-96"},"PeriodicalIF":3.7,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71428708","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Artificial intelligence for glaucoma: state of the art and future perspectives. 青光眼的人工智能治疗:现状和未来展望。

IF 3.7 2区医学

Current Opinion in Ophthalmology Pub Date : 2024-03-01 Epub Date: 2023-11-29 DOI: 10.1097/ICU.0000000000001022

Rafael Correia Barão, Ruben Hemelings, Luís Abegão Pinto, Marta Pazos, Ingeborg Stalmans

引用次数: 0

Impact of smoking on glaucoma. 吸烟对青光眼的影响。

IF 3.7 2区医学

Current Opinion in Ophthalmology Pub Date : 2024-03-01 Epub Date: 2023-11-27 DOI: 10.1097/ICU.0000000000001023

Golnoush Mahmoudinezhad, Leo Meller, Sasan Moghimi

{"title":"Impact of smoking on glaucoma.","authors":"Golnoush Mahmoudinezhad, Leo Meller, Sasan Moghimi","doi":"10.1097/ICU.0000000000001023","DOIUrl":"10.1097/ICU.0000000000001023","url":null,"abstract":"Purpose of review: Assessing whether lifestyle related factors play a role in causing primary open-angle glaucoma (POAG) is of great value to clinicians, public health experts and policy makers. Smoking is a major global public health concern and contributes to ocular diseases such as cataracts, and age-related macular degeneration through ischemic and oxidative mechanisms. Recently, smoking has been investigated as a modifiable risk factor for glaucoma. In the presence of an association with glaucoma, provision of advice and information regarding smoking to patients may help reduce the burden of disease caused by POAG. Therefore, the aim of this review is to summarize the current evidence regarding the effect of smoking in the pathogenesis of glaucoma and its incidence, progression as well as the benefits of smoking cessation.Recent findings: While the association between glaucoma development and smoking history is controversial, in the last decade, several recent studies have helped to identify possible effects of smoking, especially heavy smoking, in regard to glaucomatous progression. Smoking cessation may possibly be protective against glaucoma progression.Summary: Smoking may play a role in glaucoma progression and long-term smoking cessation may be associated with lower glaucoma progression. The dose-response relationship between smoking and glaucoma as well as therapeutic potential of smoking cessation needs to be further validated with both preclinical and rigorous clinical studies.","PeriodicalId":50604,"journal":{"name":"Current Opinion in Ophthalmology","volume":" ","pages":"124-130"},"PeriodicalIF":3.7,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10922564/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138452994","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Understanding racial disparities of glaucoma. 了解青光眼的种族差异。

IF 3.7 2区医学

Current Opinion in Ophthalmology Pub Date : 2024-03-01 Epub Date: 2023-11-03 DOI: 10.1097/ICU.0000000000001017

Viviana Barquet-Pizá, Carla J Siegfried

{"title":"Understanding racial disparities of glaucoma.","authors":"Viviana Barquet-Pizá, Carla J Siegfried","doi":"10.1097/ICU.0000000000001017","DOIUrl":"10.1097/ICU.0000000000001017","url":null,"abstract":"Purpose of review: Increased prevalence, earlier onset, and more rapid progression to vision loss from glaucoma has demonstrated racial disparity in numerous studies over decades. Precise etiologies of these important differences among patients of African and Hispanic ancestral background have not been elucidated. This review focuses on currently available epidemiologic/population, genetic, socioeconomic and physiologic studies of racial disparities in this blinding disease.Recent findings: In depth reviews of several landmark studies of glaucoma prevalence in various racial groups have highlighted potential challenges of lack of recruitment of diverse populations in genetic studies and clinical trials, challenges of racial stratification of subjects, and the impact of socioeconomic variables.Summary: Through a more comprehensive analysis of racial disparities of glaucoma, both clinicians and researchers may provide more effective population screening and management with a holistic approach for individualized patient care to provide improved outcomes. Future studies of interventions in sociodemographic factors and genetic/physiologic variables that influence the prevalence, access, and consequential vision loss from glaucoma will be crucial to minimize/eliminate racial disparities and improve outcomes for all.","PeriodicalId":50604,"journal":{"name":"Current Opinion in Ophthalmology","volume":" ","pages":"97-103"},"PeriodicalIF":3.7,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71434828","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Treatment of geographic atrophy: an update on data related to pegcetacoplan. 地理性萎缩的治疗：聚乙二醇乙酮普兰相关数据的更新。

IF 3.7 2区医学

Current Opinion in Ophthalmology Pub Date : 2024-01-01 Epub Date: 2023-10-10 DOI: 10.1097/ICU.0000000000000845

Sagar B Patel, Jeffrey S Heier, Varun Chaudhary, Charles C Wykoff

{"title":"Treatment of geographic atrophy: an update on data related to pegcetacoplan.","authors":"Sagar B Patel, Jeffrey S Heier, Varun Chaudhary, Charles C Wykoff","doi":"10.1097/ICU.0000000000000845","DOIUrl":"10.1097/ICU.0000000000000845","url":null,"abstract":"Purpose of review: Geographic atrophy is an advanced and currently untreatable form of age-related macular degeneration (AMD), which leads to significant compromise of visual function and quality of life. Dysregulation of the complement cascade has been directly implicated in AMD pathogenesis. Pegcetacoplan is a pegylated highly selective bicyclic peptide that inhibits the cleavage of complement component 3 (C3), which represents a key step in propagation of the complement cascade. The phase 2 FILLY trial as well as the phase 3 OAKS and DERBY trials have evaluated the safety and efficacy of pegcetacoplan for the treatment of GA.Recent findings: The FILLY, OAKS and DERBY trials have demonstrated that local inhibition of C3 cleavage with pegcetacoplan can reduce geographic atrophy lesion growth compared with sham with an effect size of approximately 11-35% depending on the specific trial and specific geographic atrophy phenotype considered. Overall pegcetacoplan has appeared to be well tolerated with the notable side effect of a dose-dependent increase in the rate of exudative AMD development in treated eyes.Summary: The FILLY, OAKS and DERBY trials have demonstrated that pegcetacoplan is a potentially viable treatment for geographic atrophy. Additional data from the 2-year outcomes of DERBY and OAKS as well as data from the ongoing 3-year GALE extension study will provide additional insights into the potential therapeutic benefit of pegcetacoplan. Future studies assessing complement inhibition at earlier stages of AMD, with the goal of preventing geographic atrophy formation, are warranted.","PeriodicalId":50604,"journal":{"name":"Current Opinion in Ophthalmology","volume":" ","pages":"64-72"},"PeriodicalIF":3.7,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41184081","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Patient experiences and satisfaction with cataract surgery. 患者对白内障手术的体验和满意度。

IF 3.7 2区医学

Current Opinion in Ophthalmology Pub Date : 2024-01-01 Epub Date: 2023-12-07 DOI: 10.1097/ICU.0000000000001008

Alexander C Lieu, Natalie A Afshari

引用次数: 0

An update on intraocular lens power calculations in eyes with previous laser refractive surgery. 既往激光屈光手术患者人工晶状体屈光力计算的最新进展。

IF 3.7 2区医学

Current Opinion in Ophthalmology Pub Date : 2024-01-01 Epub Date: 2023-10-11 DOI: 10.1097/ICU.0000000000001004

Daniel E Savage, Seth M Pantanelli

{"title":"An update on intraocular lens power calculations in eyes with previous laser refractive surgery.","authors":"Daniel E Savage, Seth M Pantanelli","doi":"10.1097/ICU.0000000000001004","DOIUrl":"10.1097/ICU.0000000000001004","url":null,"abstract":"Purpose of review: There is an ever-growing body of research regarding intraocular lens (IOL) power calculations following photorefractive keratectomy (PRK), laser-assisted in-situ keratomileusis (LASIK), and small-incision lenticule extraction (SMILE). This review intends to summarize recent data and offer updated recommendations.Recent findings: Postmyopic LASIK/PRK eyes have the best refractive outcomes when multiple methods are averaged, or when Barrett True-K is used. Posthyperopic LASIK/PRK eyes also seem to do best when Barrett True-K is used, but with more variable results. With both aforementioned methods, using measured total corneal power incrementally improves results. For post-SMILE eyes, the first nontheoretical data favors raytracing.Summary: Refractive outcomes after cataract surgery in eyes with prior laser refractive surgery are less accurate and more variable compared to virgin eyes. Surgeons may simplify their approach to IOL power calculations in postmyopic and posthyperopic LASIK/PRK by using Barrett True-K, and employing measured total corneal power when available. For post-SMILE eyes, ray tracing seems to work well, but lack of accessibility may hamper its adoption.","PeriodicalId":50604,"journal":{"name":"Current Opinion in Ophthalmology","volume":" ","pages":"34-43"},"PeriodicalIF":3.7,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41219258","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Intracameral antibiotics during cataract surgery: efficacy, safety, and cost-benefit considerations. 白内障手术中内窥镜抗生素:疗效、安全性和成本效益考虑。

IF 3.7 2区医学

Current Opinion in Ophthalmology Pub Date : 2024-01-01 Epub Date: 2023-10-25 DOI: 10.1097/ICU.0000000000001010

Alexander C Lieu, Jong Hwa Jun, Natalie A Afshari

{"title":"Intracameral antibiotics during cataract surgery: efficacy, safety, and cost-benefit considerations.","authors":"Alexander C Lieu, Jong Hwa Jun, Natalie A Afshari","doi":"10.1097/ICU.0000000000001010","DOIUrl":"10.1097/ICU.0000000000001010","url":null,"abstract":"Purpose of review: We summarize evidence-based considerations regarding the use of intracameral antibiotics during cataract surgery.Recent findings: The use of intraoperative intracameral antibiotics reduced the incidence of postcataract surgery endophthalmitis 3.5-fold, with an odds ratio ranging from 0.14 to 0.19. A survey of the American Society of Cataract and Refractive Surgery showed usage of intracameral injections of antibiotics increased by 16% in the United States between 2014 and 2021. The frequency of vancomycin usage has sharply dropped to 6%, while moxifloxacin is now the dominant choice at 83% among respondents. One analysis showed that 2500 patients need to be treated with intracameral antibiotics to prevent one case of endophthalmitis. A 500 μg intracameral moxifloxacin at $22 dollars per dose is cost-effective, including for patients with posterior capsular rupture (PCR).Summary: Studies substantiate the safety and efficacy of intracameral antibiotics for endophthalmitis prophylaxis. Intracameral moxifloxacin and cefuroxime are the most common choices. While vancomycin shows potential for efficacy, further studies evaluating clinical outcomes are needed. Adverse events are rare and commonly due to errors in preparation. Topical antibiotics do not provide additional prophylactic benefits to intracameral regimens. Intracameral antibiotics given alone are cost-effective.","PeriodicalId":50604,"journal":{"name":"Current Opinion in Ophthalmology","volume":" ","pages":"50-56"},"PeriodicalIF":3.7,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"50159196","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Light adjustable intraocular lenses in cataract surgery: considerations. 白内障手术中的可调光人工晶状体：注意事项。

IF 3.7 2区医学

Current Opinion in Ophthalmology Pub Date : 2024-01-01 Epub Date: 2023-11-02 DOI: 10.1097/ICU.0000000000001015

Jong Hwa Jun, Alexander Lieu, Natalie A Afshari

{"title":"Light adjustable intraocular lenses in cataract surgery: considerations.","authors":"Jong Hwa Jun, Alexander Lieu, Natalie A Afshari","doi":"10.1097/ICU.0000000000001015","DOIUrl":"10.1097/ICU.0000000000001015","url":null,"abstract":"Purpose of review: Light adjustable intraocular lens (LAL) is a promising concept in cataract surgery. This review explores considerations for the use of LALs.Recent findings: Through updates, the safety of LALs and light delivery devices have been enhanced, enabling more efficient treatment with lower ultraviolet (UV) energy. Preoperative topography and aberration are essential for understanding indications for LALs. Furthermore, when determining intraocular lens power, it is crucial to factor in potential postoperative myopia or hyperopic adjustments. This is achieved by establishing a proper postimplantation refractive target and considering potential wavefront changes. Postoperative adjustments for defocus and astigmatism have demonstrated excellent outcomes. Monovision strategy by adjustable blended vision of LALs revealed distance vision of 20/20 along with near vision of J2 in 96% of patients. However, the results of clinical studies on postrefractive cataract surgery showed contrasting outcomes at distance, indicating the need for further research results regarding its effectiveness. A new postoperative workflow needs to be designed to enable a systematic follow-up process.Summary: LALs are safe and demonstrate promising refractive outcomes. To achieve appropriate results, understanding the changes in optical characteristics associated with adjustment and constructing a new postoperative workflow are necessary.","PeriodicalId":50604,"journal":{"name":"Current Opinion in Ophthalmology","volume":" ","pages":"44-49"},"PeriodicalIF":3.7,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71428709","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Ophthalmic manifestations of Whipple's disease. 惠普尔病的眼科表现。

IF 3.7 2区医学

Current Opinion in Ophthalmology Pub Date : 2024-01-01 Epub Date: 2023-10-13 DOI: 10.1097/ICU.0000000000000989

Nailyn Rasool

引用次数: 0